Idhifa
PHONETIC PRONUNCIATION: Idhifa
Description
Idhifa: Uses, Dosage, Demographic, Side Effects, Interactions, Generic Options Idhifa (enasidenib) is a prescription medication used to treat a specific type of blood cancer called acute myeloid leukemia (AML). This medication is an oral tablet that can be taken once a day with or without food. In this article, we aim to provide medically cited information on various aspects of Idhifa. Uses of Idhifa: The primary use of Idhifa is to treat relapsed or refractory AML that carries a specific mutation in the isocitrate dehydrogenase 2 (IDH2) gene. This gene mutation causes an increase in the production of a certain protein that can promote the growth and survival of leukemia cells. Idhifa works by inhibiting this protein and thereby killing the leukemia cells. Dosage of Idhifa: The recommended starting dose of Idhifa is 100 mg taken orally once a day. The dosage may be increased to 200 mg once a day after two months of treatment if there is no response. The tablets should be swallowed whole and should not be crushed or chewed. Demographic of Idhifa: Idhifa is approved for use in adult patients with relapsed or refractory AML that carries the IDH2 mutation. The drug is not recommended for use in patients with AML without the IDH2 mutation. Side Effects of Idhifa: As with any medication, Idhifa can cause various side effects. Some common side effects include: - Nausea - Vomiting - Diarrhea - Abdominal pain - Mouth sores - Fatigue - Anemia - Decreased appetite - Electrolyte abnormalities - Increased liver enzymes Rare but serious side effects include: - Differentiation syndrome: Symptoms include fever, respiratory distress, and fluid buildup in the lungs. This can occur during the first few weeks of treatment and requires prompt treatment. - Tumor lysis syndrome: Symptoms include kidney failure, irregular heartbeats, seizures, and muscle weakness. This can occur when a large number of leukemia cells are killed off. Interactions of Idhifa: Idhifa can interact with other medications and supplements. Some medications that may interact with Idhifa include: - Rifampin: Can reduce Idhifa levels in the blood. - CYP3A4 inhibitors: Can increase Idhifa levels in the blood and increase the risk of side effects. - Antifungal agents: Can increase Idhifa levels in the blood and increase the risk of side effects. Patients should inform their healthcare provider of all medications and supplements that they are taking to avoid potential interactions. Generic Options for Idhifa: Currently, there are no generic versions of Idhifa available on the market. Conclusion: Idhifa is a medication used to treat relapsed or refractory AML with the IDH2 mutation. It is available in 100 mg and 200 mg doses and should be taken once a day. Like any medication, it can cause side effects and interact with other medications and supplements. Patients should discuss with their healthcare provider to determine if Idhifa is appropriate for their condition.
Faq for Idhifa
Idhifa (enasidenib) is a prescription medication used to treat certain types of acute myeloid leukemia (AML) in adult patients who have a specific genetic mutation called isocitrate dehydrogenase-2 (IDH2).
Idhifa works by blocking the effects of the mutated IDH2 enzyme, which helps to stop abnormal cell growth in AML.
The common side effects of Idhifa include nausea, vomiting, diarrhea, increased levels of bilirubin in the blood, abdominal pain, fatigue, decreased appetite, shortness of breath, cough, joint pain, and fever.
Idhifa is taken orally as tablets once daily with or without food. The dosage and duration of treatment will be determined by your healthcare provider.
Idhifa has shown effectiveness in treating AML with the IDH2 mutation. However, its effectiveness may vary depending on individual patient factors and response to the medication.
No, Idhifa is not approved for use in children. It is only indicated for adult patients with AML who have the IDH2 mutation.
Certain medications, such as strong CYP3A inhibitors or inducers, may interact with Idhifa and affect its effectiveness or increase the risk of side effects. It is important to inform your healthcare provider about all the medications you are currently taking.
Idhifa is generally taken until disease progression or unacceptable toxicity occurs. The duration of treatment will be decided by your healthcare provider based on your response to the medication.
Idhifa may harm the unborn baby, therefore, it is not recommended during pregnancy. It is also not known if Idhifa passes into breast milk, so breastfeeding is not advised while taking this medication.
As of now, there is no generic version of Idhifa available. It is only marketed as a brand-name medication.
The response to Idhifa may vary from person to person. It may take several weeks or months for Idhifa to start working, and the treatment duration can vary depending on individual response and the stage of leukemia.
Idhifa can cause differentiation syndrome, a potentially life-threatening condition. Other warnings include risk of embryo-fetal harm, drug interactions, and potential adverse effects on the liver. It is essential to inform your healthcare provider about any pre-existing conditions, medications, or allergies before starting Idhifa.
Idhifa may cause fetal harm if used during pregnancy and should not be used during pregnancy unless clearly necessary. It is advised to avoid breastfeeding while taking Idhifa, as it can pass into breast milk and harm the nursing infant.
The cost of Idhifa can vary depending on factors like dosage, duration of treatment, pharmacy location, and insurance coverage. It is best to check with your healthcare provider or insurance provider for specific cost details.